Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Eudocia, Lee"'
Autor:
Patrick Wen, Eudocia Lee
Publikováno v:
ESMO Open, Vol 5, Iss Suppl 4 (2020)
Externí odkaz:
https://doaj.org/article/48c4a5905845492b911582a0cb788805
Autor:
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee, Sean A Grimm, Margaret Schwartz, Kirsten L Bell Burdett, Rimas V Lukas, Karan Dixit, Isabella Perron, Hui Zhang, William J Gradishar, Elena I Pentsova, Suriya Jeyapalan, Morris D Groves, Michelle Melisko, Jeffrey J Raizer
Publikováno v:
Neuro-Oncology. 25:557-565
Background Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS pen
Autor:
Fabio Iwamoto, Shyam Tanguturi, Arati Desai, Lakshmi Nayak, Erik Uhlmann, Tony Wang, Robert Lustig, Lauren Hertan, Stephen Bagley, Julia Hayden, Corey Laforest-Roys, Alona Muzikansky, Christine McCluskey, Ugonma Chukwueke, J Ricardo McFaline-Figueroa, Eudocia Lee, Patrick Y Wen, David Reardon
Publikováno v:
Neuro-Oncology. 24:vii63-vii64
Re-irradiation is therapeutically considered for select rGBM patients and may induce immunogenic cell death to stimulate anti-tumor immune responses. Our phase 2 study of re-irradiation with pembrolizumab among rGBM patients evaluated the efficacy an
Autor:
J Ricardo McFaline-Figueroa, Robert Prins, Yu Qiao, Lu Sun, Gang Li, Jiyoon Kim, Eudocia Lee, Lakshmi Nayak, Ugonma Chukwueke, Rameen Beroukhim, Tracy Batchelor, E Antonio Chiocca, Lisa Doherty, Jennifer Stefanik, Kathryn Partridge, Amanda Spearman, Maria Lavallee, Alexa Myers, Corey Laforest-Roys, Rachel Fox Garcia, Wenya Linda Bi, Omar Arnaout, Pierpaolo Peruzzi, G Rees Cosgrove, Keith Ligon, Isabel Arrillaga-Romany, Jennifer Clarke, David A Reardon, Timothy Cloughesy, Patrick Y Wen
Publikováno v:
Neuro-Oncology. 24:vii65-vii66
Glioblastoma is immunologically “cold”, with little clinical response to single-agent immune-checkpoint inhibitors (ICI). Our previous randomized study of neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab in recurrent glioblast
Autor:
Jamie A Dean, Shyam K Tanguturi, Daniel Cagney, Kee-Young Shin, Gilbert Youssef, Ayal Aizer, Rifaquat Rahman, Lubna Hammoudeh, David Reardon, Eudocia Lee, Jorg Dietrich, Kaoru Tamura, Masaru Aoyagi, Lacey Wickersham, Patrick Y Wen, Paul Catalano, Daphne Haas-Kogan, Brian M Alexander, Franziska Michor
Publikováno v:
Neuro-oncology.
Background Glioblastomas comprise heterogeneous cell populations with dynamic, bidirectional plasticity between treatment-resistant stem-like and treatment-sensitive differentiated states, with treatment influencing this process. However, current tre
Autor:
Ingo K. Mellinghoff, Brian Alexander, Donald Berry, Nicholas Blondin, Meredith Buxton, Webster Cavenee, Howard Colman, John de Groot, Macarena I. de la Fuente, Benjamin Ellingson, Gary Gordon, Emma M.V. Hyddmark, Mustafa Khasraw, Andrew Lassman, Eudocia Lee, Wenbin Li, Michael Lim, Tom Mikkelsen, Apoorva Nelli, James Perry, Erik Sulman, Kirk Tanner, Michael Weller, Patrick Y. Wen, Timothy Cloughesy
Publikováno v:
Cancer Research. 83:CT062-CT062
Background: GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform trial designed to rapidly identify experimental therapi
Autor:
Priya U, Kumthekar, Michael J, Avram, Andrew B, Lassman, Nancy U, Lin, Eudocia, Lee, Sean A, Grimm, Margaret, Schwartz, Kirsten L, Bell Burdett, Rimas V, Lukas, Karan, Dixit, Isabella, Perron, Hui, Zhang, William J, Gradishar, Elena I, Pentsova, Suriya, Jeyapalan, Morris D, Groves, Michelle, Melisko, Jeffrey J, Raizer
Publikováno v:
Neuro-oncology.
Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS penetration. T
Autor:
Eudocia Lee, Michelle Rudek, Veronica Rendo, Nicholas Khuu, Tobias Walbert, Matthias Holdhoff, Frank Lieberman, Arati Desai, Roy Strowd, Emily Lapinskas, Kristine Pelton, William Pisano, Serena Desideri, Neeraja Danda, Joy Fisher, Xiaobu Ye, L Burt Nabors, Stuart Grossman, Rameen Beroukhim, Brian Alexander, Keith Ligon, Patrick Y Wen
Publikováno v:
Neuro-Oncology. 24:vii76-vii76
BACKGROUND KRT232 is an orally bioavailable, selective small molecule inhibitor of MDM2 that blocks the protein-protein interaction between MDM2 and p53. We performed a surgical window of opportunity trial of KRT232 in patients with recurrent GBM. ME
Autor:
Patrick Y Wen, David A Reardon, Deborah Forst, Eudocia Lee, Teresa Daoud, Tamara Berthoud, Catalina Soare, Francisco Diaz-Mitoma, David E Anderson, Andrew Lassman, Fabio Iwamoto
Publikováno v:
Neuro-Oncology. 24:vii62-vii62
Cytomegalovirus (CMV) antigens have been reported in over 90% of GBMs. CD4+ and CD8+ T cells are most frequently directed against the gB and pp65 antigens, respectively, which are immunogenic targets in a CMV-based GBM immunotherapeutic. First-recurr
Autor:
Veronica Rendo, Eudocia Lee, Nicholas Khuu, Kristine Pelton, Emily Lapinskas, Patrick Y Wen, Keith Ligon, Rameen Beroukhim
Publikováno v:
Neuro-Oncology. 24:vii213-vii213
Over 60% of glioblastomas retain wild-type p53, resulting in potential susceptibility to MDM2 inhibitors. These molecules disrupt the interaction between p53 and its negative regulator MDM2, allowing downstream pathway signaling and cell fate decisio